Abstract
ObjectiveTo assess the incremental cost and cost-effectiveness of continuous and discontinuous regimens of bevacizumab (Avastin) and ranibizumab (Lucentis) for neovascular age-related macular degeneration (nAMD) from a UK National Health Service...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have